The 10 year average is for a single indication for a new drug. Anavex should be obtaining approval for several indications in the next year.
Parallel development does slow down the overall pace a bit but the multiple approvals should more than make up for that small delay, assuming that approvals are obtained.
Market Data 
Markets 
AI
